For example, recent developments to target and inhibit NF-κB in the ovarian cancer or disruption of the NF-κB/IL-8 signaling in breast cancer can potential targeted therapy for CSCs [94,95,96]. Here, NFKB1 is linked to ovarian carcinoma.